GORTEC-REACH study results fail to change the current standard of care for locally advanced SCCHN
Adding an immune checkpoint inhibitor to cetuximab plus radiotherapy does not improve outcomes versus standard of care in locally advanced squamous cell carcinoma of the head and neck